Patient-reported outcome measures add value as clinical trial endpoints
- PMID: 40855193
- DOI: 10.1038/s41591-025-03906-1
Patient-reported outcome measures add value as clinical trial endpoints
Conflict of interest statement
Competing interests: This Comment emerged from an initiative of the PROTEUS Consortium. The PROTEUS Consortium is funded by independent education grants from Pfizer, which had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication. N.L.C., A.L.R.S., C.S. and M.B. receive funding through their institutions related to their PROTEUS roles. A.W.W. and E.T. receive an honorarium as PROTEUS Steering Committee members. C.S. currently receives personal consulting fees from Movember and previously received personal consulting fees from Shionogi, and has received travel costs for meeting presentations from Shionogi and Executive Insight Healthcare Consultants. J.B. reports personal consulting fees for Avant Garde Health and Asahi Intecc, and research support from Inari medical. D.K. reports research support from the National Institute for Health and Care Research, Kidney Research UK, and the Nuffield Foundation. L.N. is a stockholder in GSK. R.C.C. reports personal consulting fees from Janssen and Novartis. A.M.C., S.C.R. and C.M. declare no competing interests.
References
LinkOut - more resources
Full Text Sources